Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Evaluation of Safety and Durable Immunogenicity of Melanoma Vaccination, With or Without Systemic CDX-1127, in Patients With Stage II-IV Melanoma

Trial Profile

Evaluation of Safety and Durable Immunogenicity of Melanoma Vaccination, With or Without Systemic CDX-1127, in Patients With Stage II-IV Melanoma

Recruiting
Phase of Trial: Phase I/II

Latest Information Update: 22 Nov 2018

At a glance

  • Drugs Peptide vaccines (Primary) ; Peptide vaccines (Primary) ; Varlilumab (Primary) ; Cyclophosphamide; Montanide ISA-51; Montanide ISA-51
  • Indications Malignant melanoma
  • Focus Adverse reactions; Pharmacodynamics
  • Acronyms Mel-65
  • Most Recent Events

    • 13 Nov 2018 Status changed from not yet recruiting to recruiting.
    • 31 Oct 2018 Planned initiation date changed from 1 Sep 2018 to 29 Oct 2018.
    • 14 Aug 2018 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top